The increasing burden of potentially preventable liver disease among adult liver transplant recipients: A comparative analysis of liver transplant indication by era in Australia and New Zealand

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 2, 2016, Pages 434-441

  Howell, Jessica ^a,b,c,d   Balderson, Glenda ^e   Hellard, Margaret ^c   Gow, Paul ^a,b   Strasser, Simone ^f   Stuart, Katherine ^e   Wigg, Alan ^g   Jeffrey, Gary ^h   Gane, Ed ⁱ   Angus, Peter W ^a,b  

^a AUSTIN HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c BURNET INSTITUTE   (Australia)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e PRINCESS ALEXANDRA HOSPITAL   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g FLINDERS MEDICAL CENTRE   (Australia)

^h Charles Gardiner Hospital   (Australia)

ⁱ AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Epidemiology; Liver cirrhosis; Prevention; Public health; Transplantation

Indexed keywords

ADULT; ALCOHOLIC FATTY LIVER; ARTICLE; AUSTRALIA; COMPARATIVE STUDY; CONTROLLED STUDY; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER GRAFT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; NEW ZEALAND; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROSPECTIVE STUDY; ADOLESCENT; ALCOHOL LIVER DISEASE; COST OF ILLNESS; LIVER DISEASES; LIVER RESECTION; PREVALENCE; PRIMARY PREVENTION; SECONDARY PREVENTION; STATISTICS AND NUMERICAL DATA; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AUSTRALIA; COST OF ILLNESS; HEPATECTOMY; HEPATITIS C; HUMANS; LIVER DISEASES; LIVER DISEASES, ALCOHOLIC; LIVER TRANSPLANTATION; NEW ZEALAND; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; PRIMARY PREVENTION; SECONDARY PREVENTION; TIME FACTORS; YOUNG ADULT;

EID: 84955610990     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13082     Document Type: Article

References (66)

1. Lucey MR, Terrault N, Ojo L et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013; 19(1): 3-26.
2. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 2008; 14(Suppl 2): S36-44.
3. Murray KF, Carithers RL, Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41(6): 1407-32.
4. Howell JA, Gow PJ, Angus PW et al. Early-onset versus late-onset nonanastomotic biliary strictures post liver transplantation: risk factors reflect different pathogenesis. Transpl. Int. 2012; 25(7): 765-75.
5. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53(3): 1020-2.
6. Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 2013; 95(5): 755-60.
7. Burra P, Germani G, Adam R et al. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J. Hepatol. 2013; 58(2): 287-96.
8. EASL. Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol. 2014; 60(2): 392-420.
9. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 2011; 17(2): 107-15.
10. Visconti AJ, Doyle JS, Weir A, Shiell AM, Hellard ME. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia. J. Gastroenterol. Hepatol. 2013; 28(4): 707-16.
11. Iversen J, Wand H, Topp L, Kaldor J, Maher L. Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study. Am. J. Public Health 2013; 103(8): 1436-44.
12. Kwon JA, Anderson J, Kerr CC et al. Estimating the cost-effectiveness of needle-syringe programs in Australia. AIDS 2012; 26(17): 2201-10.
13. Lichtenstein B. Needle exchange programs: New Zealand's experience. Am. J. Public Health 1996; 86(9): 1319.
14. Alavi M, Grebely J, Micallef M et al. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. Clin. Infect. Dis. 2013; 57(Suppl 2): S62-9.
15. van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS 2010; 24(12): 1799-812.
16. Afdhal NH, Zeuzem S, Schooley RT et al. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J. Viral Hepat. 2013; 20(11): 745-60.
17. Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 2014; 370(20): 1889-98.
18. Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N. Engl. J. Med. 2014; 370(21): 1993-2001.
19. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2006; 354(10): 1001-10.
20. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006; 354(10): 1011-20.
21. Lai CL, Gane E, Liaw YF et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007; 357(25): 2576-88.
22. Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 2008; 359(23): 2442-55.
23. Hellard M, Doyle JS, Sacks-Davis R, Thompson AJ, McBryde E. Eradication of hepatitis C infection: the importance of targeting people who inject drugs. Hepatology 2014; 59(2): 366-9.
24. Rolls DA, Sacks-Davis R, Jenkinson R et al. Hepatitis C transmission and treatment in contact networks of people who inject drugs. PLoS One 2013; 8(11):e78286.
25. Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med. 2014; 370(3): 211-21.
26. Gane EJ, Stedman CA, Hyland RH et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014; 146(3): 736-43 e1.
27. EASL. Clinical practical guidelines: management of alcoholic liver disease. J. Hepatol. 2012; 57(2): 399-420.
28. Sheron N, Gilmore I, Parsons C, Hawkey C, Rhodes J. Projections of alcohol-related deaths in England and Wales-tragic toll or potential prize? Lancet 2012; 379(9817): 687-8.
29. Fagan KJ, Irvine KM, Kumar S et al. Assessment of alcohol histories obtained from patients with liver disease: opportunities to improve early intervention. Intern. Med. J. 2013; 43(10): 1096-102.
30. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction 1993; 88(6): 791-804.
31. Anton RF, O'Malley SS, Ciraulo DA et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295(17): 2003-17.
32. Addolorato G, Leggio L, Ferrulli A, Caputo F, Gasbarrini A. The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opin. Investig. Drugs 2009; 18(5): 675-86.
33. Addolorato G, Leggio L, Ferrulli A et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370(9603): 1915-22.
34. Kaner EF, Dickinson HO, Beyer F et al. The effectiveness of brief alcohol interventions in primary care settings: a systematic review. Drug Alcohol Rev. 2009; 28(3): 301-23.
35. Kaner E, Bland M, Cassidy P et al. Screening and brief interventions for hazardous and harmful alcohol use in primary care: a cluster randomised controlled trial protocol. BMC Public Health 2009; 9: 287.
36. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am. J. Gastroenterol. 2010; 105(1): 14-32; quiz 3.
37. Pessione F, Ramond MJ, Peters L, et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int. 2003; 23(1): 45-53.
38. Jiang H, Livingston M, Room R, Dietze P, Norstrom T, Kerr WC. Alcohol consumption and liver disease in Australia: a time series analysis of the period 1935-2006. Alcohol Alcohol. 2014; 49(3): 363-8.
39. Anderson P, Chisholm D, Fuhr DC. Effectiveness and cost-effectiveness of policies and programmes to reduce the harm caused by alcohol. Lancet 2009; 373(9682): 2234-46.
40. Verrill C, Markham H, Templeton A, Carr NJ, Sheron N. Alcohol-related cirrhosis-early abstinence is a key factor in prognosis, even in the most severe cases. Addiction 2009; 104(5): 768-74.
41. Bhala N, Angulo P, van der Poorten D et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; 54(4): 1208-16.
42. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55(6): 2005-23.
43. Farrell GC, Chitturi S, Lau GK, Sollano JD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J. Gastroenterol. Hepatol. 2007; 22(6): 775-7.
44. Farrell GC, Wong VW, Chitturi S. NAFLD in Asia-as common and important as in the West. Nat. Rev. Gastroenterol. Hepatol. 2013; 10(5): 307-18.
45. Suzuki A, Angulo P, Lymp J et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 2005; 41(1): 64-71.
46. Whalley S, Puvanachandra P, Desai A, Kennedy H. Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. Clin. Med. 2007; 7(2): 119-24.
47. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 2013.
48. Kemmer N, Neff GW, Franco E et al. Nonalcoholic fatty liver disease epidemic and its implications for liver transplantation. Transplantation 2013; 96(10): 860-2.
49. Agopian VG, Kaldas FM, Hong JC et al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann. Surg. 2012; 256(4): 624-33.
50. LaMattina JC, Foley DP, Fernandez LA et al. Complications associated with liver transplantation in the obese recipient. Clin. Transplant. 2012; 26(6): 910-8.
51. Vanwagner LB, Bhave M, Te HS, Feinglass J, Alvarez L, Rinella ME. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology 2012; 56(5): 1741-50.
52. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49(1): 306-17.
53. Sevastianos VA, Hadziyannis SJ. Nonalcoholic fatty liver disease: from clinical recognition to treatment. Expert Rev. Gastroenterol. Hepatol. 2008; 2(1): 59-79.
54. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst. Rev. 2010(1): CD007340.
55. de Jonge C, Rensen SS, Koek GH et al. Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2013; 11(11): 1517-20.
56. Rabl C, Campos GM. The impact of bariatric surgery on nonalcoholic steatohepatitis. Semin. Liver Dis. 2012; 32(1): 80-91.
57. MacLachlan JH, Allard N, Towell V, Cowie BC. The burden of chronic hepatitis B virus infection in Australia, 2011. Aust. N. Z. J. Public Health 2013; 37(5): 416-22.
58. Lucas CR, Milne A, Hopkirk N. Kawerau revisited: hepatitis A and B seroprevalence in 1984 and 1993. N. Z. Med. J. 1994; 107(981): 266-8.
59. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30(12): 2212-9.
60. Papatheodoridis GV, Dimou E, Dimakopoulos K et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42(1): 121-9.
61. Chang TT, Liaw YF, Wu SS et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52(3): 886-93.
62. Winstock AR, Anderson CM, Sheridan J. National survey of HIV and hepatitis testing and vaccination services provided by drug and alcohol agencies in Australia. Med. J. Aust. 2006; 184(11): 560-2.
63. Vu LH, Gu Z, Walton J et al. Hepatitis B knowledge, testing, and vaccination among Chinese and Vietnamese adults in Australia. Asia Pac. J. Public Health 2012; 24(2): 374-84.
64. Giles ML, Sasadeusz JJ, Garland SM, Grover SR, Hellard ME. An audit of obstetricians' management of women potentially infected with blood-borne viruses. Med. J. Aust. 2004; 180(7): 328-32.
65. EASL-EORTC. Clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012; 56(4): 908-43.
66. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005; 55(2): 74-108.